Drug intelligence / Profile preview

SB-000

Development stage: Preclinical
Lead developer: Shift Bioscience
Modality: Gene Therapies

Overview

SB-000 is an adeno-associated virus (AAV) gene therapy candidate being developed by Shift Bioscience for the treatment of age-related hearing loss. The therapy utilizes Shift Bioscience's proprietary machine-learning platform to identify and deliver a specific anti-aging gene (currently unnamed) that can reverse the epigenetic age of cells. By overexpressing this target within the auditory system, SB-000 aims to rejuvenate aged cells and potentially restore hearing function. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on SB-000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB-000.

Explore the full profile